Pfizer posts Phase 3 data for Lyme vaccine candidate LB6V at IDWeek 2026
PFE•Pfizer said Phase 3 results for its LB6V Lyme disease vaccine candidate support its ability to protect against Lyme disease. The EMA began reviewing the candidate’s marketing application in August 2026.
1. Lyme vaccine results
Pfizer flagged Phase 3 results for LB6V, its Lyme disease vaccine candidate, with presentations scheduled for Oct. 22 at IDWeek 2026. The readout supported the vaccine’s ability to protect against Lyme disease, and the EMA started reviewing its marketing application in August 2026.
2. Other conference data
Separate IDWeek presentations will cover Phase 2 data for Pfizer’s 25-valent pediatric pneumococcal vaccine candidate, with results previously announced in May 2026. Pfizer also highlighted Phase 3 findings for an LP.8.1-adapted Comirnaty formulation in at-risk children.
